دورية أكاديمية
Pharmacokinetics of high-titer anti-SARS-CoV-2 human convalescent plasma in high-risk children
| العنوان: | Pharmacokinetics of high-titer anti-SARS-CoV-2 human convalescent plasma in high-risk children |
|---|---|
| المؤلفون: | Gordon, Oren, Brosnan, Mary Katherine, Yoon, Steve, Jung, Dawoon, Littlefield, Kirsten, Ganesan, Abhinaya, Caputo, Christopher A, Li, Maggie, Morgenlander, William R, Henson, Stephanie N, Ordonez, Alvaro A, De Jesus, Patricia, Tucker, Elizabeth W, Peart Akindele, Nadine, Ma, Zexu, Wilson, Jo, Ruiz-Bedoya, Camilo A, Younger, M Elizabeth M, Bloch, Evan M, Shoham, Shmuel, Sullivan, David, Tobian, Aaron Ar, Cooke, Kenneth R, Larman, Ben, Gobburu, Jogarao Vs, Casadevall, Arturo, Pekosz, Andrew, Lederman, Howard M, Klein, Sabra L, Jain, Sanjay K |
| المصدر: | United States |
| بيانات النشر: | American Society for Clinical Investigation |
| سنة النشر: | 2021 |
| المجموعة: | UMB Digital Archive (University of Maryland, Baltimore) |
| مصطلحات موضوعية: | COVID-19, Immunoglobulins, Infectious disease |
| الوصف: | Background: While most children experience mild COVID-19, high-risk children with underlying conditions may develop severe disease, requiring interventions. Kinetics of antibodies transferred via COVID-19 convalescent plasma early in disease, have not been characterized. Methods: In this study (NCT04377672), high-risk children were prospectively enrolled to receive high-titer COVID-19 convalescent plasma (>1:320 anti-spike IgG; Euroimmun). Passive transfer of antibodies and endogenous antibody production were serially evaluated for up to 2 months after transfusion. Commercial and research ELISA assays, virus neutralization assays, high-throughput phage-display assay utilizing a coronavirus epitope library and pharmacokinetic analyses were performed. Results: Fourteen high-risk children (median age 7.5 years) received high-titer COVID-19 convalescent plasma, nine children within five days (range 2-7) of symptom onset and five children within 4 days (range 3-5) after exposure to SARS-CoV-2. There were no serious adverse events related to transfusion. Antibodies to SARS-CoV-2 were transferred from the donor to the recipient, but antibody titers declined by 14-21 days with a 15.1-day t½ for spike protein IgG. Donor plasma had significant neutralization capacity which was transferred to the recipient. However, as early as 30 minutes post-transfusion, recipient plasma had low neutralization capacity. Conclusions: Convalescent plasma transfused to high-risk children appears to be safe with expected antibody kinetics, regardless of weight or age. However, current use of convalescent plasma in high-risk children achieves low neutralizing capacity. ; https://doi.org/10.1172/jci.insight.151518Test |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | JCI Insight; http://hdl.handle.net/10713/17319Test |
| DOI: | 10.1172/jci.insight.151518 |
| الإتاحة: | https://doi.org/10.1172/jci.insight.151518Test http://hdl.handle.net/10713/17319Test |
| رقم الانضمام: | edsbas.B1A23820 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1172/jci.insight.151518 |
|---|